Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Puente, J. (Hospital Clínico San Carlos (Madrid))
Pinto, Alvaro (Hospital Universitario La Paz (Madrid))
Mendez-Vidal, María José (Hospital Universitario Reina Sofía (Còrdova, Espanya))
García del Muro, Xavier (Hospital Universitari de Bellvitge)
Maroto Rey, Pablo (Institut de Recerca Sant Pau)
Vazquez, Sergio (Hospital Universitario Lucus Augusti (Lugo))
Luque-Caro, Raquel (Hospital Universitario Virgen de las Nieves (Granada))
Anido, Urbano (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Strunz-McKendry, Torsten (Astellas Pharma Europe Ltd (Surrey, Regne Unit))
Upadhyay, Anil (Astellas Pharma Europe Ltd (Surrey, Regne Unit))
Montes, Jose (Effice Research (Madrid))
Ortiz Nuñez, Aurora (Astellas Pharma Europe Ltd (Surrey, Regne Unit))
González Portela, Judit (Astellas Pharma Europe Ltd (Surrey, Regne Unit))
Castellano, Daniel (Hospital 12 de Octubre (Madrid))
Universitat Autònoma de Barcelona

Fecha:	2024
Resumen:	Real-world evidence on locally advanced or metastatic urothelial carcinoma (la/mUC) management in Spain is limited. This study describes patient characteristics, treatment patterns, survival, and health care resource utilization (HCRU) in this population. This retrospective observational study included all adults with a first diagnosis/record of la/mUC (index date) from January 2015 to June 2020 at nine university hospitals in Spain. Data were collected up to December 31, 2020 (end of study), death, or loss to follow-up. Patient characteristics, treatment patterns, median overall survival (OS) and progression-free survival (PFS) from index date (Kaplan-Meier estimates), and disease-specific HCRU were described. Among 829 patients, median age at diagnosis was 71 years; 70. 2% had ≥ 1 comorbidity, and 52. 5% were eligible for cisplatin. Median follow-up was 12. 7 months. Most (84. 7%) patients received first-line systemic treatment; of these, 46. 9% (n = 329) received second-line and 16. 6% (n = 116) received third-line therapy. Chemotherapy was the most common treatment in all lines of therapy, followed by programmed cell death protein 1/ligand 1 inhibitors. Median (95% confidence interval) OS and PFS were 18. 8 (17. 5-21. 5) and 9. 9 (8. 9-10. 5) months, respectively. Most patients required ≥ 1 outpatient visit (71. 8%), inpatient admission (56. 6%), or emergency department visit (56. 5%). Therapeutic patterns were consistent with Spanish guideline recommendations. Chemotherapy had a role in first-line treatment of la/mUC in Spain during the study period. However, the disease burden remains high, and new first-line treatments recommended in the latest European guidelines should be made available to patients in Spain.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Chemotherapy ; Medical records ; Metastatic neoplasm ; Observational study ; Urinary bladder neoplasms
Publicado en:	Clinical & translational oncology, 2024 , ISSN 1699-3055

DOI: 10.1007/s12094-024-03734-8
PMID: 39365365

9 p, 726.0 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados